COMPUGEN LEADS CONSORTIUM TO MODEL CANCER RELATED KINASE PATHWAY

Compugen Ltd. has announced that it is leading a consortium for the development of a platform to simulate the MAP-kinase pathway, a signaling pathway related to cancer which is already targeted by a number of cancer therapies and diagnostic tests. The Simulation Modeling of the MAP-kinase Pathway (SIMAP) consortium is funded by the European Commission which has allocated 3.1 million Euro for the project over a three year period.
PharmacoGenomicsOnline